Chinese Vaccine Ad5-Ncov Approved for Trials in Russia: Interfax


Russia has granted approval for clinical trials to be held for the Chinese COVID-19 vaccine Ad5-Ncov involving 8,000 volunteers, Reuters reported, citing the Interfax news agency.

Ad5-nCoV is a vaccine candidate co-developed by CanSino Biologics and a Chinese military-backed research unit.